NasdaqGS - Nasdaq Real Time Price USD

ORIC Pharmaceuticals, Inc. (ORIC)

5.16
+0.43
+(9.20%)
As of 3:53:43 PM EDT. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for ORIC

Recent News: ORIC

View More
ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates

ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates
GlobeNewswire 13 days ago
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 16 days ago
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire 20 days ago
Is ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) the Best Biotech Penny Stock to Buy According to Hedge Funds?

Is ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) the Best Biotech Penny Stock to Buy According to Hedge Funds?
Insider Monkey last month
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire last month
ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire last month
Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth

Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth
Simply Wall St. last month
ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones

ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones
GlobeNewswire 2 months ago
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates
GlobeNewswire 2 months ago
Oric Pharmaceuticals announces clinical supply agreement with Janssen

Oric Pharmaceuticals announces clinical supply agreement with Janssen
TipRanks 4 months ago
ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones

ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones
GlobeNewswire 4 months ago
View More

Related Tickers

CGEM Cullinan Therapeutics, Inc.
7.74
+3.20%
 
OLMA Olema Pharmaceuticals, Inc.
4.8200
+2.34%
 
ZNTL Zentalis Pharmaceuticals, Inc.
1.2350
-1.98%
 
ERAS Erasca, Inc.
1.2500
-2.75%
 
KYMR Kymera Therapeutics, Inc.
30.22
-0.10%
 
GBIO Generation Bio Co.
0.4015
+5.30%
 
DSGN Design Therapeutics, Inc.
3.5000
-0.28%
 
NRIX Nurix Therapeutics, Inc.
9.58
+0.16%
 
ITOS iTeos Therapeutics, Inc.
8.34
+6.79%
 
RLAY Relay Therapeutics, Inc.
2.9300
+4.27%